TinyGemsBreaks Archive - Page 108 of 121

FridayAug 12, 2022 1:30 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses

Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this medical problem “through the creation of immune reprogramming technologies, which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases) and allergens,” a recent article reads. “While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s…

FridayAug 12, 2022 12:40 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success

CNS Pharmaceuticals (NASDAQ: CNSP) is currently recruiting patients for a phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating glioblastoma multiforme (“GBM”), the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain. Recently, the company announced that the FDA had approved an amendment to the study’s protocol, boosting its Berubicin clinical development program. “The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy,” explains a recent article. “The key objectives of the amendment, according to CNS Pharmaceuticals…

ThursdayAug 11, 2022 12:14 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation Metrics

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company today issued information to its stakeholders as an aid to conveniently research and understand various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. “Biotech companies with little to no revenue can still be worth billions,” Raphael Rottgen, CFA, FRM, was quoted in the press release. “While valuations can be extremely low or extremely high, there is often underlying logic in identifying risks and arriving at those valuations. Developing new drugs can have significant costs of over $1 billion and can take…

ThursdayAug 11, 2022 10:28 am

TinyGemsBreaks – GreenBox POS (NASDAQ: GBOX) Announces Participation in Upcoming Q3 Investor Summit

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, will be presenting at the upcoming Q3 Investor Summit. The two-day event, which is slated for Aug. 16–17, 2022, is hosted by Investor Summit Group. GreenBox chair Ben Errez will be presenting virtually; his presentation is scheduled for Aug. 17, 2022, at 12:30 p.m. ET. In addition, Errez will host one-on-one meetings with investors during the summit. The Q3 Investor Summit is designed to connect companies with leading investors. To view the webcast, visit https://ibn.fm/ZR6NV To view the full press release, visit https://ibn.fm/nQfoR About GreenBox POS GreenBox is an emerging financial technology…

WednesdayAug 10, 2022 12:35 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of a positive full written response from the Food and Drug Administration (“FDA”) from its pre-Investigational New Drug (“Pre-IND”) meeting regarding DehydraTECH-CBD for the treatment of hypertension. According to the update, the FDA confirmed agreement with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway for its program. This is advantageous because the abbreviated pathway, as it is often described, typically enables a faster route to commercial approval than the traditional 505(b)(1) NDA pathway. “We are very pleased to have received…

WednesdayAug 10, 2022 12:16 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Earnings Conference Call, Webcast

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, has scheduled a conference call and webcast to discuss its earnings for the first half of 2022. The call is slated for Monday, Aug. 15, 2022, at 4:30 p.m. ET. the company plans to release its financial report and numbers prior to the call. During the call, company officials will discuss the financial and operations results as well as provide an update on the company’s operations, house of brands and life sciences strategies; the event will also include time for a Q&A. An…

TuesdayAug 09, 2022 1:11 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Preliminary Q3 Results

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced preliminary third-quarter results. According to the update, in addition to recent highlights and successes for the company and its EV programs, Mullen is in a strong financial position, with approximately $99 million in cash and cash equivalents on hand as of Aug. 8, 2022. Among the highlights, the company reported asset growth of 391% and positive working capital of $27,656,446. “It’s an exciting and pivotal time for Mullen as we continue to experience exceptional growth,” said David Michery, CEO and chairman of Mullen Automotive. “We’ve been focused on…

TuesdayAug 09, 2022 12:37 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the appointment of Nicole Lemerond to its board of directors, effective immediately. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. Throughout her career, she has established and led health care groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Concurrent with Lemerond’s appointment, Adam Cutler has decided to transition off the board of directors. Cutler has served…

TuesdayAug 09, 2022 11:53 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue and sell up to $35 million of common shares. According to the announcement, the shares can be sold “from time to time” through the Neo Exchange, the NYSE American LLC or any other “marketplace” upon which the shares are listed, quoted or traded, at the prevailing market price at the time of sale. The company anticipates using any proceeds from the sales of these shares for growth opportunities and working capital initiatives. In addition, Cybin…

TuesdayAug 09, 2022 10:12 am

TinyGemsBreaks — Cepton Technologies Inc. (NASDAQ: CPTN) Releases Q2 2022 Financial Report, Corporate Update

Cepton Technologies (NASDAQ: CPTN) is reporting its financial results for the second quarter 2022, the period ended June 30, 2022; the report also included business updates for the Silicon Valley innovator and leader in high-performance Micro Motion Technology(RM) (“MMT”) lidar solutions. Highlights of the report included news of CPTN’s OEM Series production execution, including continued ramp of D-sample shipments for end delivery to multiple OEM vehicle manufacturing plants across multiple states as well as the completion of a lead-OEM site audit of the company’s Japan manufacturing facility; in addition, the report noted that Cepton has selected Fabrinet as key submodule supplier…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks